Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs) have enabled major advances that have reshaped the treatment of several advanced-stage solid tumours. Considering the intended rationale behind the design of ADCs, which is to achieve targeted delivery of cytotoxic molecules by linking them to antibodies targeting...
Alternative Titles
Full title
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2824687886
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2824687886
Other Identifiers
ISSN
1759-4774
E-ISSN
1759-4782
DOI
10.1038/s41571-023-00783-w
